Articles tagged "B cells"

2021 American Transplant Congress
Development of a Rat Model of Antibody-Mediated Rejection After Liver Transplantation
T. Tajima, K. Hata, J. Kusakabe, H. Miyauchi, S. Uemoto
Dept. of Surgery, Div. of HBP Surgery & Transplantation, Kyoto University Graduate School of Medicine, Kyoto, Japan
*Purpose: Antibody-mediated rejection (AMR) is a refractory rejection after donor-specific antibody (DSA)-positive or ABO blood-type incompatible liver transplantation (LT), due at least in part to…
2021 American Transplant Congress
Iguratimod Prevents Antibody-mediated Rejection by Regulating Germinal Center Formation and Antibody Production
H. Zhang, A. Chandraker, P. Sage, N. Murakami
Transplantation Research Center, Brigham and Women's Hospital, Boston, MA
*Purpose: Antibody-mediated rejection (ABMR) is a major cause of chronic renal allograft failure without effective treatment, and developing a novel therapy is an urgent need.…
2021 American Transplant Congress
The Effect of Daratumumab (Dara, Humanized Anti-CD38 Monoclonal Antibody) on Immune Cells In Vitro and in a HLA-Sensitized Kidney Transplant Patient (HS KTx Pt) Desensitized (DES) with Dara
S. Ge¹, M. Chu¹, A. De Guzman¹, E. Ortiz¹, A. Vo², N. Ammerman², S. C. Jordan², M. Toyoda¹
¹Transplant Immunology Laboratory, Cedars Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Antibody-Mediated Rejection (ABMR), primarily mediated by B cells, plasma cells (PC) and antibodies (Ab), is an obstacle for successful transplantation in HS KTx Pts.…
2021 American Transplant Congress
Selective Bcl-2 Inhibition for Induction of Mixed Chimerism and Renal Allograft Tolerance without Myelosupression
G. Lassiter¹, T. Hirose¹, H. Sasaki¹, D. Ma¹, T. Oura¹, A. Dehnadi¹, A. Cosimi¹, P. Cippa², T. Fehr³, T. Kawai¹
¹Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ²Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland, ³Division of Nephrology, University of Zurich, Zurich, Switzerland
*Purpose: Immunologic tolerance of renal allograft has been achieved by induction of hematopoietic chimerism through donor bone marrow transplantation (DBMT). The myeloablative and genetic toxicity…
2021 American Transplant Congress
Intrarenal B-cell Activating Factor (BAFF) Levels are Increased in Transplant Glomerulopathy
S. Panzer, K. Swanson, G. Pandya, L. Hidalgo, S. Reese
University of Wisconsin Madison, Madison, WI
*Purpose: Transplant glomerulopathy (TG), a key feature of chronic active antibody-mediated rejection (caABMR), is associated with allograft failure. B-cell activating factor (BAFF) is a cytokine…
2021 American Transplant Congress
Evaluation of Rituximab-abbs in Renal Transplant: A Case Series
A. Dao¹, B. Jimenez², A. Reyad¹, J. Guiteau¹, M. Madhrira³, N. Umezurike¹, S. Patel¹, S. Allam³
¹Transplant, Medical City Fort Worth, Fort Worth, TX, ²College of Pharmacy, University of North Texas, Fort Worth, TX, ³Tarrant Nephrology Associates, Premier Physicians Group Health, Fort Worth, TX
*Purpose: Biosimilars are FDA-approved alternatives to cost-prohibitive biologics, with no clinically meaningful differences in safety, purity, and potency. Rituximab-abbs, a biosimilar to rituximab, has labeled…
2021 American Transplant Congress
Contribution of T-bet Expressing CD27+ CD21- Activated Memory B Cells Poised for Plasma Cell Differentiation to Antibody-mediated Rejection of Kidney Transplants
K. Louis¹, E. Bailly¹, C. Macedo¹, B. Ramaswami¹, X. Gu¹, G. Chalasani¹, A. Zeevi¹, P. Randhawa¹, H. Singh², C. Lefaucheur³, D. Metes¹
¹Surgery, University of Pittsburgh, Pittsburgh, PA, ²Center for Systems immunology, Department of Immunology, University of Pittsburgh, Pittsburgh, PA, ³Human Immunology and Immunopathology, INSERM U976, Paris, France
*Purpose: Alloimmunity triggered by donor-specific antibodies (DSAs) and ensuing development of antibody-mediated rejection (ABMR) are detrimental to organ transplants. Yet, the cellular states underlying B…
2021 American Transplant Congress
TOLS are Novel Regulatory TLOs with A B Cell Signature
I. Rosales¹, Q. Yuan¹, C. Yang¹, P. Russell¹, J. Madsen¹, A. Alessandrini¹, R. Colvin¹, -. AA and RC²
¹Massachusetts General Hospital, Boston, MA, ²Co-Senior Authors, Boston, MA
*Purpose: Our previous studies suggest that a DBA/2 kidney graft is accepted by a MHC-fully mis-matched C57/BL6 recipient. Accepted renal allografts exhibited lymphoid like structures…
2021 American Transplant Congress
CD40 Blockade by the Fc-Silent Immunosuppressive Antibody Iscalimab Results in Diminished B Cell Activation and Differentiation and is Paralleled by Whole Blood Gene Expression Data
R. Kraaijeveld¹, M. W. van den Hoogen¹, A. E. de Weerd¹, E. Ferroro², G. Robert², U. Laessing², B. Haraldsson², J. S. Rush², C. C. Baan¹
¹Erasmus MC, Rotterdam, Netherlands, ²Novartis Pharmaceuticals AG, Basel, Switzerland
*Purpose: Blockade of costimulatory molecule CD40 by the Fc-silent immunosuppressive drug Iscalimab has shown to inhibit acute alloreactivity in non-human primates and is currently being…
2021 American Transplant Congress
Belatacept and Carfilzomib-based Treatment of Active Antibody-mediated Rejection in a Sensitized Nonhuman Primate Model
J. Kwun¹, R. Schmitz¹, M. Manook¹, Z. Fitch¹, D. Olaso¹, A. Choi¹, J. Yoon¹, Y. Bae¹, J. Lambris², S. Knechtle¹
¹Surgery, Duke University, Durham, NC, ²Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
*Purpose: One third of sensitized, HLA-incompatible transplant recipients experience antibody-mediated rejection (AMR) with limited effective treatment options. We tested a novel treatment strategy for AMR…

« Previous Page
1
…
4
5
6
7
8
…
35
Next Page »